Sarah Abbas is collaborating with Nervosave Therapeutics as Chief Medical Officer for the clinical development of NVO-101 program. She is also medical officer at the Institute for Stem Cell and Monogenic Diseases, Corbeil-Essonnes, France.

Sarah Abbas obtained her medical degree in 1992 in tropical and infectious diseases at University of Paris School of Medicine – Hôpital Lariboisière, Paris, France. After a brief carreer as field physician in HIV disease, in the early 2000‘s she teamed up with Gustave Roussy Institute, Paris, France, and Pfizer Global Pharmaceuticals, Paris, France to develop clinical oncology drugs and anti-infective and respiratory franchises (Zyvox®, Vfend® and Zithromax®). In 2005, she joined Roche Pharmaceuticals France, Neuilly, France, to head the development of anti-HIV and cystic fibrosis franchises. In 2007, she pursued her search for a commercial treatment for cystic fibrosis at Chiesi Farmaceutici S.p.A., Parma, Italy, as Corporate Clinical Project leader. She also developed compounds to fight neonatal respiratory distress. In 2008 she joined Astellas Pharma, Levallois-Perret, France, as Medical Affairs group Manager for anti-infective products. She developed, implemented, and oversaw medical strategy in line with Global Marketing strategy for the entire Anti-infective franchise. In 2010 she moved toward innovative therapy development as Medical director for Immunology and Biotherapy at UCB Biosciences Inc., Brussels, Belgium. Here, she wrote and implemented trial protocols for monoclonal antibodies and TNF blockers to treat several severe autoimmune diseases (lupus, Crohn disease, rheumatoid polyarthritis, spondyloarthritis). After 8 years she next worked as External Clinical Study Director for Sanofi-Aventis, Chilly-Mazarin, France to setup clinical trial for drugs to treat diabetes, rare diseases and inflammation.

In 2018 she decided to invest the field of innovative therapies from the biotech side and joined Da Volterra, Paris, France, as Clinical Study Director. This biotech develops compounds to prevent microbiota dysbiosis. Then she joined Genethon and Institute for Stem Cell and Monogenic Diseases, both institutes supported by AFM-Telethon charity institution, to setup clinical trials for ATMPs (Advanced Therapy Medicinal Products). Her development included gene and cell/tissues therapies for rare diseases Wiscott-Aldrich syndrome, chronic granulomatous disease, several myopathies, retinitis pigmentosa, Wolfram syndrome and sickle cell anemia.

Beside her engagement for the development of innovative therapies for rare diseases, Sarah dedicated herself in the 90’s as head of several humanitarian medical missions in Africa (Rwanda, Burundi, Congo, Zaire) and Asia (Cambodia) for Doctors without Borders, WHO and UNICEF. She setup emergency refugee medical programs in Rwanda and developed and implemented several public health programs in for infectious diseases control and vaccination and educational program for pregnant women.